Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
03/2003
03/26/2003EP1294740A2 Chemically-modified antimicrobial peptides, compositions and methods of production and use
03/26/2003EP1294728A1 HMG-CoA REDUCTASE INHIBITORS AND METHOD
03/26/2003EP1294721A1 Cyclic gmp-specific phosphodiesterase inhibitors
03/26/2003EP1294714A2 Thrombin receptor antagonists
03/26/2003EP1294711A2 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as as modulators of protein kinases
03/26/2003EP1294707A2 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
03/26/2003EP1294698A1 Fused azepine derivatives and their use as antidiuretic agents
03/26/2003EP1294697A1 1,2,3,5-tetrahydrobenzo[c]azepin-4-one derivatives having muscarinic antagonist activity
03/26/2003EP1294691A1 Serine protease inhibitors
03/26/2003EP1294689A1 Novel $g(b crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same
03/26/2003EP1294679A1 Beta-amino acid nitrile derivatives
03/26/2003EP1294398A2 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
03/26/2003EP1294397A2 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
03/26/2003EP1294389A1 THERAPEUTICAL USE OF i SOPHORA FLAVESCENS /i OR i SOPHORA SUBPROSTRATA /i EXTRACTS
03/26/2003EP1294388A1 EXTRACTS FROM i SOPHORA /i SPECIES, METHOD FOR PRODUCING THE SAME AND THEIR USE
03/26/2003EP1294357A1 Bioavailable dosage form of isotretinoin
03/26/2003EP1200431B1 Quinuclidine derivatives and their use as muscarinic m3 receptors ligands
03/26/2003EP1150701A4 Homing pro-apoptotic conjugates and methods of using same
03/26/2003EP1027325B1 Lipophilic diesters of chelating agents
03/26/2003EP1025085B1 Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof
03/26/2003CN1406230A 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
03/26/2003CN1406229A Pyrimidine compounds
03/26/2003CN1406225A Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
03/26/2003CN1404868A Chinese medicinal preparation for treating pyretic stranguria
03/26/2003CN1404851A Medicine for treating kidney disease
03/26/2003CN1404831A Use of Radix scutellariae glycoside in preparing medicine for treating prostatic disorders and its medicinal composition
03/26/2003CN1103590C Use of thiazolidinediones to prevent or delay on set of NIDDM
03/26/2003CN1103589C Method for modulating human sexual response
03/25/2003WO2002026260A1 Preventives/remedies for emotional disorders
03/25/2003US6538009 Pyrazole derivatives as anti-inflammatory/analgesic agents
03/25/2003US6538004 Potassium channel modulators relax smooth muscle cells and inhibit bladder contractions; treating nervous, eating, cardiovascular, gastrointestinal, and sexual disorders
03/25/2003US6537984 Contacting a targeted solid tumor cell population with a combination of a vinca alkaloid selected from vinblastine, vincristine, vinorelbine, and a triptolide in combination dosage to reduce the targeted tumor cell population
03/25/2003US6537982 Method of treating prostatic diseases using active vitamin D analogues
03/25/2003CA2423364A1 Preventives/remedies for emotional disorders
03/25/2003CA2149052C Dry mix formulation for bisphosphonic acids
03/25/2003CA2107961C Injectable mesna solutions
03/20/2003WO2003023404A1 A method of diagnosis and treatment and agents useful for same
03/20/2003WO2003023014A2 Human ion channels
03/20/2003WO2003023008A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/20/2003WO2003022877A1 Crystal structure of baff, and use thereof in drug design
03/20/2003WO2003022852A2 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
03/20/2003WO2003022835A1 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
03/20/2003WO2003022821A1 Heterocycle derivative having 20-hete-producing enzyme inhibitory activity
03/20/2003WO2003022801A1 Reverse hydroxamic acid derivatives
03/20/2003WO2003022297A1 Biodegradable implant comprising a polylactide polymer and a lh-rh analogue
03/20/2003WO2003022291A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
03/20/2003WO2003022270A1 Transdermal administration of an enalapril ester
03/20/2003WO2003022266A1 Hypoestoxides, derivatives and agonists thereof for use as inhibitors of angiongenesis
03/20/2003WO2003022259A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
03/20/2003WO2003022253A1 Dosage forms having prolonged active ingredient release
03/20/2003WO2003022123A2 Methods of kidney transplantation utilizing developing nephric tissue
03/20/2003WO2003004046A3 Use of xaa-pro peptidases for the treatment of substance p-related disorders
03/20/2003WO2003000195A3 Method and material for treating immune diseases
03/20/2003WO2002091993A3 Estrogen receptor modulators
03/20/2003WO2002066040A8 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
03/20/2003WO2002020736A3 Proteases
03/20/2003WO2002018445A9 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
03/20/2003US20030055286 Il-8 receptor antagonists
03/20/2003US20030055260 Il-8 receptor antagonists
03/20/2003US20030055248 Il-8 receptor antagonists
03/20/2003US20030055245 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof
03/20/2003US20030055227 Process for obtaining lignan
03/20/2003US20030055108 Contacting cultured prostate cancer cells with the omega-3 fatty acid; monitoring transactivating ability of an androgen receptor, wherein decrease in transactivating ability is indicative of inhibitory effect by omega-3 fatty acid
03/20/2003US20030055098 Method of treatment
03/20/2003US20030055093 For therapy of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction
03/20/2003US20030055091 Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators
03/20/2003US20030055086 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
03/20/2003US20030055080 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
03/20/2003US20030055068 Pyrazole compounds useful as protein kinase inhibitors
03/20/2003US20030055054 CXCR3 antagonists
03/20/2003US20030055048 Compositions and methods for treating or preventing convulsions or seizures
03/20/2003US20030055035 Useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions
03/20/2003US20030055024 Administering in divided doses an effective amount of a vascular damaging agent or a pharmaceutically acceptable salt thereof for production of a vascular damaging effect in a warm-blooded animal such as a human
03/20/2003US20030055006 Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use
03/20/2003US20030055003 Administering copper chelator and activated protein C (APC) or protein C or agent that increases the synthesis of protein C in the animal, or both, an activator of protein C for therapy
03/20/2003US20030054990 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
03/20/2003US20030054974 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/20/2003US20030054046 Hydrated dressing containing metal microbiocide
03/20/2003US20030054011 Anticancer agents
03/20/2003CA2460348A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
03/20/2003CA2460190A1 Transdermal administration of an enalapril ester
03/20/2003CA2460092A1 A method of diagnosis and treatment and agents useful for same
03/20/2003CA2459890A1 Crystal structure of baff, and use thereof in drug design
03/20/2003CA2459560A1 Methods of kidney transplantation utilizing developing nephric tissue
03/20/2003CA2451454A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/19/2003EP1293511A1 Canine liver cell growth factor
03/19/2003EP1293510A1 Novel polypeptide and its dna
03/19/2003EP1292679A1 A g-protein coupled receptor
03/19/2003EP1292678A2 G-protein coupled receptors
03/19/2003EP1292581A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists
03/19/2003EP1292572A1 Propanolaminotetralines, preparation thereof and compositions containing same
03/19/2003EP1292564A2 Aminoalcohol derivatives
03/19/2003EP1292363A2 Carboxyalkylether-acat inhibitor combinations
03/19/2003EP1292324A2 Critical illness neuropathy
03/19/2003EP1292315A2 Methods and compositions using sulodexide for the treatment of diabetic nephropathy
03/19/2003EP1178984B1 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
03/19/2003EP1177195B1 1-AMINO TRIAZOLO 4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV
03/19/2003EP1080069B1 Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
03/19/2003EP0973390A4 Retinoid related molecules for the inhibition of endothelin-1 overproduction in disease
03/19/2003EP0964678B1 Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
1 ... 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 ... 562